Steve C F Au-Yeung
Overview
Explore the profile of Steve C F Au-Yeung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wei Y, Poon D, Fei R, Lam A, Au-Yeung S, To K
Sci Rep
. 2016 May;
6:25363.
PMID: 27150583
Three molecular targeted tyrosine kinase inhibitors (TKI) were conjugated to classical platinum-based drugs with an aim to circumvent TKI resistance, predominately mediated by the emergence of secondary mutations on oncogenic...
2.
Wei Y, To K, Au-Yeung S
J Pharmacol Sci
. 2015 Dec;
129(4):210-5.
PMID: 26644081
Imatinib, a multitargeted tyrosine kinase inhibitor, exhibits potent anticancer activity against leukemia harboring the Bcr-Abl oncogene and some solid tumors overexpressing c-kit and PDGFR. However, its clinical efficacy is severely...
3.
Pang S, Yu C, Guan H, Au-Yeung S, Ho Y
Oncol Rep
. 2008 Oct;
20(5):1269-76.
PMID: 18949432
Novel demethylcantharidin-platinum (DMC-Pt) complexes have been found to have superior in vitro anticancer activity against a number of human colon cancer cell lines when compared with oxaliplatin. One complex where...
4.
Pang S, Yu C, Au-Yeung S, Ho Y
Biochem Biophys Res Commun
. 2007 Sep;
363(1):235-40.
PMID: 17868646
Oxaliplatin is a third generation platinum (Pt) drug with a diaminocyclohexane (DACH) entity, which has recently obtained worldwide approval for the clinical treatment of colon cancer, and apparently operates by...
5.
Wang X, Au-Yeung S, Ho Y
J Inorg Biochem
. 2007 Apr;
101(6):909-17.
PMID: 17428541
The pharmacokinetics and tissue distribution profiles of a novel series of traditional Chinese medicine-platinum (TCM-Pt) compounds [Pt(C(8)H(8)O(5))(NH(2)R)(2)]: 1 (where R=H), 3 (R=CH(3)) and 5 (R=C(6)H(10)), were studied in Sprague-Dawley rats...
6.
To K, Au-Yeung S, Ho Y
Anticancer Drugs
. 2006 Aug;
17(6):673-83.
PMID: 16917213
A series of novel traditional Chinese medicine-platinum compounds has been found to be active against a number of murine and human cancers both in vitro and in vivo. Their high...
7.
Yu C, Li K, Pang S, Au-Yeung S, Ho Y
Bioorg Med Chem Lett
. 2006 Jan;
16(6):1686-91.
PMID: 16386904
A series of platinum complexes derived from integrating demethylcantharidin (DMC) with different isomers of 1,2-diaminocyclohexane (DACH) has been synthesized and found to exhibit superior in vitro anticancer activity against colorectal...
8.
To K, Ho Y, Au-Yeung S
Anticancer Drugs
. 2005 Aug;
16(8):825-35.
PMID: 16096430
Protein phosphatase 2A (PP2A) is a new target for platinum (Pt)-based cancer chemotherapeutic agents. A series of novel Pt complexes containing demethylcantharidin, a modified component of a traditional Chinese medicine...
9.
To K, Ho Y, Au-Yeung S
Cancer Lett
. 2005 May;
223(2):227-37.
PMID: 15896457
A novel series of TCM-platinum complexes [Pt(C8H8O5)(NH2R)2] 1-5, designed from incorporating demethylcantharidin, a modified component from a traditional Chinese medicine (TCM) with a platinum moiety was found to circumvent cisplatin...
10.
To K, Wang X, Yu C, Ho Y, Au-Yeung S
Bioorg Med Chem
. 2004 Sep;
12(17):4565-73.
PMID: 15358284
Novel TCM-platinum compounds [Pt(C(8)H(8)O(5))(NH(2)R)(2)] 1-5, derived from integrating demethylcantharidin, a modified component from a traditional Chinese medicine (TCM) with a platinum moiety, possess anticancer and protein phosphatase 2A inhibition properties....